Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Yoshinami T, Nozawa K, Yokoe T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Yoshinami T, et al. Among authors: ichihara e. Int J Clin Oncol. 2024 Jun;29(6):681-688. doi: 10.1007/s10147-024-02504-4. Epub 2024 Apr 23. Int J Clin Oncol. 2024. PMID: 38649648
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM. Konduri K, et al. Among authors: ichihara e. Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21. Cancer Discov. 2016. PMID: 27102076 Free PMC article.
Early palliative care in non-small-cell lung cancer.
Ichihara E, Matsuoka J, Kiura K. Ichihara E, et al. N Engl J Med. 2010 Dec 2;363(23):2263; author reply 2264-5. doi: 10.1056/NEJMc1010529. N Engl J Med. 2010. PMID: 21121847 No abstract available.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
Saito K, Takigawa N, Ohtani N, Iioka H, Tomita Y, Ueda R, Fukuoka J, Kuwahara K, Ichihara E, Kiura K, Kondo E. Saito K, et al. Among authors: ichihara e. Mol Cancer Ther. 2013 Aug;12(8):1616-28. doi: 10.1158/1535-7163.MCT-12-1239. Epub 2013 Jun 12. Mol Cancer Ther. 2013. PMID: 23761220
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K. Zhang D, et al. Among authors: ichihara e. Cancer Lett. 2011 Oct 28;309(2):228-35. doi: 10.1016/j.canlet.2011.06.006. Epub 2011 Jun 24. Cancer Lett. 2011. PMID: 21742432
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Harada D, Takigawa N, Ochi N, Ninomiya T, Yasugi M, Kubo T, Takeda H, Ichihara E, Ohashi K, Takata S, Tanimoto M, Kiura K. Harada D, et al. Among authors: ichihara e. Cancer Sci. 2012 Oct;103(10):1795-802. doi: 10.1111/j.1349-7006.2012.02363.x. Epub 2012 Jul 24. Cancer Sci. 2012. PMID: 22712764 Free PMC article.
175 results